NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
Updated: Sep 27, 2022
The OPTIMISMM trial
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Sponsor
Multiple Locations
International Study
NCT01734928: Phase 3: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)
Official Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : November 28, 2012
PMID: 31097405
Lancet Oncol; June 2019
PMID: 28642620
Leukemia; Dec 2017